Booth No.5N-12
CategoryOutsourcing

Dr. Reddy's Laboratories Ltd.

Booth No.:5N-12
Category:Outsourcing
Company Information
Email: api@drreddys.com TEL: Address: 500034
8-2-377, Road, No.3, Banjara Hills, Hyderabad INDIA
URL: http://api.drreddys.com
Contact in Japan
Japan agent: Dr Reddys Laboratories Japan Email: api@drreddys.com TEL: +81-90-2590-0206 Address: 5-1, NIHOMBASHIKABUTOCHO KABUTOCHO NO.1 HEIWA BLDG. 3F. CHUO-KU, TOKYO,
With a portfolio of more than 200 commercially available APIs, Dr. Reddy’s API unit caters to leading innovator and generic companies across the US, Europe, Latin America, Japan, Korea and other emerging markets. With deep technical strengths in the development of complex APIs such as steroids, peptides, complex long chain and highly potent molecules we consistently deliver high-quality APIs and formulations. For more information log on to: www.api.drreddys.com.

Company information

Address 500034
8-2-377, Road, No.3, Banjara Hills, Hyderabad INDIA
URL http://api.drreddys.com
Email api@drreddys.com
Product Classification APALUTAMIDENew
APIXABANNew
APREMILAST New
DABIGATRANNew
DAPAGLIFLOZINNew
EMPAGLIFLOZIN New
ENZALUTAMIDENew
LENVATINIBNew
LINAGLIPTIN New
LUBIPROSTONENew
MIRABEGRONNew
MONTELUKASTNew
NILOTINIBNew
PALBOCICLIBNew
RelugolixNew
SITAGLIPTIN New
SUGAMMADEXNew
Tafamidis New
TOFACITINIB New
VENETOCLAX New

Contact in Japan

Japan Agent Dr Reddys Laboratories Japan
Address 5-1, NIHOMBASHIKABUTOCHO KABUTOCHO NO.1 HEIWA BLDG. 3F. CHUO-KU, TOKYO,
TEL +81-90-2590-0206
Email api@drreddys.com

Product introduction

APALUTAMIDENewAPIXABANNewAPREMILAST NewDABIGATRANNewDAPAGLIFLOZINNewEMPAGLIFLOZIN NewENZALUTAMIDENewLENVATINIBNewLINAGLIPTIN NewLUBIPROSTONENewMIRABEGRONNewMONTELUKASTNewNILOTINIBNewPALBOCICLIBNewRelugolixNewSITAGLIPTIN NewSUGAMMADEXNewTafamidis NewTOFACITINIB NewVENETOCLAX New

Exhibitor's Presentation

〈Free of charge〉 Same day registration

If you would like to attend, please come directly to the seminar venue.

    April 17(Wed.) 13:00 - 13:30 【6B】
    Strategic advantage for Japanese companies to partner with Indian manufacturers for sustainable patient access.